Restoring mitochondrial quantity and quality to reverse the Warburg effect and drive neuroblastoma differentiation

H Haowen Jiang (Department of Radiation Oncology, Stanford University) S Sarah Jane Tiche (Department of Surgery, Stanford University) C Clifford Jiajun He (Department of Radiation Oncology, Stanford University) J Junyan Liu (Department of Radiation Oncology, Stanford University) F Fuyun Bian (Department of Ophthalmology, Stanford University) M Mohamed Jedoui (Department of Radiation Oncology, Stanford University) B Balint Forgo (Department of Pathology, Stanford University) M Md Tauhidul Islam (Department of Radiation Oncology, Stanford University) M Meng Zhao P Pamela Emengo B Bo He Y Yang Li A Albert M. Li (Department of Radiation Oncology, Stanford University) A Anh T. Truong (Agilent Technologies) J Jestine Ho (Agilent Technologies) C Cathyrin Simmermaker (Agilent Technologies) Y Yanan Yang (Agilent Technologies) M Meng-Ning Zhou (Department of Radiation Oncology, Stanford University) Z Zhen Hu (Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 0B8, Canada) K Katrin J. Svensson D Daniel J. Cuthbertson (Agilent Technologies) F Florette K. Hazard (Department of Pathology, Stanford University) L Lei Xing (Department of Radiation Oncology, Stanford University) H Hiroyuki Shimada (Department of Pathology, Stanford University) B Bill Chiu (Department of Surgery, Stanford University) J Jiangbin Ye (Department of Radiation Oncology, Stanford University)

Abstract

Reduced mitochondrial quality and quantity in tumors is associated with dedifferentiation and increased malignancy. However, it remains unclear how to restore mitochondrial quantity and quality in tumors and whether mitochondrial restoration can drive tumor differentiation. Our study shows that restoring mitochondrial function using retinoic acid (RA) to boost mitochondrial biogenesis and a mitochondrial uncoupler to enhance respiration synergistically drives neuroblastoma differentiation and inhibits proliferation. U- 13 C-glucose/glutamine isotope tracing revealed a metabolic shift from the pentose phosphate pathway to oxidative phosphorylation, accelerating the tricarboxylic acid cycle and switching substrate preference from glutamine to glucose. These effects were abolished by electron transport chain (ETC) inhibitors or in ρ 0 cells lacking mitochondrial DNA, emphasizing the necessity of mitochondrial function for differentiation. Dietary RA and uncoupler treatment promoted tumor differentiation in an orthotopic neuroblastoma xenograft model, evidenced by neuropil production and Schwann cell recruitment. Single-cell RNA sequencing of xenografts revealed that this strategy effectively eliminated the stem cell population, promoted differentiation, and increased mitochondrial gene signatures along the differentiation trajectory, potentially improving patient outcomes. Collectively, our findings establish a mitochondria-centric therapeutic strategy for inducing tumor differentiation, suggesting that maintaining/driving differentiation in tumor requires not only ATP production but also continuous ATP consumption and sustained ETC activity.

Article Details

Volume / Issue Vol. 122, Issue 36
Published September 09, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (26)

H

Haowen Jiang

Department of Radiation Oncology, Stanford University

S

Sarah Jane Tiche

Department of Surgery, Stanford University

C

Clifford Jiajun He

Department of Radiation Oncology, Stanford University

J

Junyan Liu

Department of Radiation Oncology, Stanford University

F

Fuyun Bian

Department of Ophthalmology, Stanford University

M

Mohamed Jedoui

Department of Radiation Oncology, Stanford University

B

Balint Forgo

Department of Pathology, Stanford University

M

Md Tauhidul Islam

Department of Radiation Oncology, Stanford University

M

Meng Zhao

P

Pamela Emengo

B

Bo He

Y

Yang Li

A

Albert M. Li

Department of Radiation Oncology, Stanford University

A

Anh T. Truong

Agilent Technologies

J

Jestine Ho

Agilent Technologies

C

Cathyrin Simmermaker

Agilent Technologies

Y

Yanan Yang

Agilent Technologies

M

Meng-Ning Zhou

Department of Radiation Oncology, Stanford University

Z

Zhen Hu

Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 0B8, Canada

K

Katrin J. Svensson

D

Daniel J. Cuthbertson

Agilent Technologies

F

Florette K. Hazard

Department of Pathology, Stanford University

L

Lei Xing

Department of Radiation Oncology, Stanford University

H

Hiroyuki Shimada

Department of Pathology, Stanford University

B

Bill Chiu

Department of Surgery, Stanford University

J

Jiangbin Ye

Department of Radiation Oncology, Stanford University